Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Index funds carry risks for retirees, including sequence of returns and drawdown volatility. Learn strategies to mitigate these concerns.
22,062 articlesAbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
When a lockup period ends, insiders can sell their shares, creating potential price swings. This article breaks down ...
Adobe and Duolingo sit at opposite ends of the tech stock spectrum: one is a cash-generating powerhouse, the other a ...
CryptoQuant says MicroStrategy’s aggressive Bitcoin purchases risk cash strain in a volatile market, calling on Micro...
A data-driven model now sees roughly 36% upside for Qualcomm stock within a year, even after a choppy period around i...
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
A sudden stock pullback creates a rare entry point for patient investors. The company combines non-discretionary serv...
Apple quietly hiking prices on Mac and iPad models signals a shift in pricing strategy as memory costs rise, with inv...
Micron Technology surprised markets with a standout quarter, sending its stock higher and helping steady a volatile A...
NOWPayments and KoinX launch Crypto Tax Educational Assets to help global merchants navigate crypto tax rules as cros...
A senior couple built treasury ladder to secure steady, government-backed income as yields climb, yet the Medicare IR...
What happens when AI breakthroughs and high-flying tech bets collide with political markets? This article explains th...